​

Funding Round

Series D - Phagenesis

Series D - Phagenesis

Investment Firm

Overview

Phagenesis is engaged in the development of a device to treat dysphagia, a condition that disables the safe swallowing of food.

Announced Date

Mar 04, 2024

Closed on Date

Mar 04, 2024

Funding Type

Series D

Highlights

N/A

Location

N/A

Social

N/A

Investor Lead

EQT Life Sciences

EQT Life Sciences

EQT Life Sciences is a debt and early_stage_venture and late_stage_venture and post_ipo and venture firm.

Sectoral Asset Management

Sectoral Asset Management

Sectoral Asset Management is a early_stage_venture and late_stage_venture and post_ipo firm.

Participant Investors

5

Investor Name
Participant InvestorNorthern Gritstone
Participant InvestorSectoral Asset Management
Participant InvestorAphelion Capital
Participant InvestorBritish Patient Capital
Participant InvestorEQT Life Sciences

Round Details and Background

Phagenesis raised $42000000 on 2024-03-04 in Series D

Phagenesis is engaged in the development of a device to treat dysphagia, a condition that disables the safe swallowing of food.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Mar 04, 2024
Series D - Phagenesis
5-42.0M
May 22, 2013
Series B - Phagenesis
1-17.0M
Oct 04, 2011
Series B - Phagenesis
1-9.3M
Sep 01, 2010
Series A - Phagenesis
-3.1M

Recent Activity

There is no recent news or activity for this profile.